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•  I	  do	  not	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  salary	  compensa/on	  from	  
anyone	  other	  than	  my	  current	  employer,	  CSHL	  .	  	  
	  
•  Any	  revenue	  that	  I	  earn	  from	  providing	  medical	  
care	  in	  Utah	  is	  donated	  to	  UFBR	  for	  gene/cs	  
research.	  
Industrializa/on	  of	  Genome	  Sequencing	  –	  
Just	  like	  what	  happened	  in	  development	  of	  
MRI	  
•  09/11/12
Illumina	  Announces	  Expedited	  Individual	  Genome	  
Sequencing	  Service	  (IGS)	  
•  09/11/12
Illumina	  and	  Partners	  HealthCare	  Announce	  Alliance	  to	  
Introduce	  Next-­‐Genera/on	  Sequencing	  Clinical	  
Interpreta/on	  and	  Repor/ng	  Tools	  
•  09/11/12
Illumina	  Launches	  TruSightTM	  Targeted	  Sequencing	  
Content	  Sets	  
•  Seguin	  E.	  1866,	  Idiocy	  and	  its	  treatment	  by	  the	  
physiological	  method.	  
•  -­‐	  	  “our	  incomplete	  studies	  do	  not	  permit	  
actual	  classiﬁca/on;	  but	  it	  is	  be`er	  to	  leave	  
things	  by	  themselves	  rather	  than	  to	  force	  
them	  into	  classes	  which	  have	  their	  founda/on	  
only	  on	  paper”.	  
OBSERVATIONS ON AN ETHNIC CLASSIFICATION OF IDIOTS *
J. LANGDON H. DOWN M.D., London
THOSE who have given any attention to congenital mental lesions, must have
been frequently puzzled how to arrange, in any satisfactory way, the different
classes of this defect which may have come under their observation. Nor
will the difficulty be lessened by an appeal to what has been written on the
subject. The systems of classification are generally so vague and artificial,
that, not only do they assist but feebly, in any mental arrangement of the
phenomena which are presented, but they completely fail in exerting anypractical influence on the subject.
The medical practitioner who may be consulted in any given case, has,
perhaps in a very early condition of the child's life, to give an opinion on
points of vital importance as to the present condition and probable future of
the little one. Moreover, he may be pressed as to the question, whether the
supposed defect dates from any cause subsequent to the birth or not. Has
the nurse dosed the child with opium? Has the little one met with any
accident? Has the instrumental interference which maternal safety de-
manded, been the cause of what seems to the anxious parents, a vacant future?
Can it be that when away from the family attendant the calomel powders
were judiciously prescribed? Can, in fact, the strange anomalies which the
child presents, be attributed to the numerous causes which maternal solici-
tude conjures to the imagination, in order to account for a condition, for
which any cause is sought, rather than hereditary taint or parental influence.
Will the systems of classification, either all together, or any one of them,
assist the medical adviser in the opinion he is to present, or the suggestions
which he is to tender to the anxious parent? I think that they will entirely
fail him in the matter, and that he will have in many cases to make a guarded
diagnosis and prognosis, so guarded, in fact, as to be almost valueless, or to
venture an authoritative assertion which the future may perhaps confirm.
I have for sometime had my attention directed to the possibility of
making a classification of the feeble minded by arranging them around
various ethnic standards—in other words, framing a natural system to
supplement the information to be derived by an inquiry into the history of
the case.
I have been able to find among the large number of idiots and imbeciles
which come under my observation, both at Earlswood and the out-patient
department of the Hospital, that a considerable portion can be fairly re-
ferred to one of the great divisions of the human family other than the class
from which they have sprung. Of course, there are numerous representatives
of the great Caucasian family. Several well-marked examples of the Ethi-
opian variety have come under my notice, presenting the characteristic
malar bones, the prominent eyes, the puffy lips, and retreating chin. The
* This paper from the London Hospital Clinical Report 3, 259-262 (i866) is republishedon account of its historical interest (see page 698). The editors are indebted to Dr J. H.
Edwards, The Medical School, University of Birmingham who proposed republication and
provided the copy.
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The life expectancy, however, is far below the average, and the tendency is
to the tuberculosis, which I believe to be the hereditary origin of the
degeneracy.Apart from the practical bearing of this attempt at an ethnic classification,
considerable philosophical interest attaches to it. The tendency in the
present day is to reject the opinion that the various races are merely varieties
of the human family having a common origin, and to insist that climatic,
or other influences, are insufficient to account for the different types of man.
Here, however, we have examples of retrogression, or at all events, of de-
parture from one type and the assumption of the characteristics of another.
If these great racial divisions are fixed and definite, how comes it that disease
is able to break down the barrier, and to simulate so closely the features os
the members of another division. I cannot but think that the observations
which I have recorded are indications that the differences in the races are not
specific but variable.
These examples of the result of degeneracy among mankind, appear to me
to furnish some arguments in favour of the unity of the human species.
London Hospital Cli ical Lecture Report. 3, 259-262, i866.
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“Those	  who	  hav 	  given	  any	  a` n/ n	  to	  congenital	  mental	  
lesions,	  must	  have	  been	  frequently	  puzzled	  how	  to	  arrange,	  in	  
any	  sa/sfactory	  way,	  the	  diﬀerent	  classes	  of	  this	  defect	  which	  
may	   ave	  come	  under	  their	  observa/on.	  Nor	  will	  the	  diﬃculty	  be	  
lessened	  by	  an	  appeal	  to	  what	  has	  been	  wri`en	  on	  the	  subject.	  
The	  systems	  of	  classiﬁca/on	  are	  generally	  so	  vague	  and	  ar/ﬁcial,	  
that,	  not	  only	  do	  they	  assist	  but	  feebly,	  in	  any	  mental	  
arra gement	  of	  the	  phenomena	  represented,	  but	  they	  
completely	  fail	  in	  exer/ng	  a y	  prac/cal	  inﬂuenc 	  on	  the	  subject.”	  
	  
	  
Diagnos(c	  Criteria	  for	  299.00	  Au(s(c	  Disorder	  
	  
Diagnos(c	  and	  Sta(s(cal	  Manual	  of	  Mental	  Disorders:	  DSM	  IV	  
	  (I)	  A	  total	  of	  six	  (or	  more)	  items	  from	  (A),	  (B),	  and	  (C),	  with	  at	  least	  two	  from	  (A),	  and	  one	  each	  from	  (B)	  and	  (C)	  
	  
(A)	  qualita/ve	  impairment	  in	  social	  interac/on,	  as	  manifested	  by	  at	  least	  two	  of	  the	  following:	  
1.	  marked	  impairments	  in	  the	  use	  of	  mul/ple	  nonverbal	  behaviors	  such	  as	  eye-­‐to-­‐eye	  gaze,	  facial	  expression,	  body	  posture,	  and	  gestures	  to	  
regulate	  social	  interac/on	  
2.	  failure	  to	  develop	  peer	  rela/onships	  appropriate	  to	  developmental	  level	  
3.	  a	  lack	  of	  spontaneous	  seeking	  to	  share	  enjoyment,	  interests,	  or	  achievements	  with	  other	  people,	  (e.g.,	  by	  a	  lack	  of	  showing,	  bringing,	  or	  
poin/ng	  out	  objects	  of	  interest	  to	  other	  people)	  	  
4.	  lack	  of	  social	  or	  emo/onal	  reciprocity	  (	  note:	  in	  the	  descrip/on,	  it	  gives	  the	  following	  as	  examples:	  not	  ac/vely	  par/cipa/ng	  in	  simple	  
social	  play	  or	  games,	  preferring	  solitary	  ac/vi/es,	  or	  involving	  others	  in	  ac/vi/es	  only	  as	  tools	  or	  "mechanical"	  aids	  )	  
	  
(B)	  qualita/ve	  impairments	  in	  communica/on	  as	  manifested	  by	  at	  least	  one	  of	  the	  following:	  	  
1.	  delay	  in,	  or	  total	  lack	  of,	  the	  development	  of	  spoken	  language	  (not	  accompanied	  by	  an	  a`empt	  to	  compensate	  through	  alterna/ve	  
modes	  of	  communica/on	  such	  as	  gesture	  or	  mime)	  
2.	  in	  individuals	  with	  adequate	  speech,	  marked	  impairment	  in	  the	  ability	  to	  ini/ate	  or	  sustain	  a	  conversa/on	  with	  others	  
3.	  stereotyped	  and	  repe//ve	  use	  of	  language	  or	  idiosyncra/c	  language	  
4.	  lack	  of	  varied,	  spontaneous	  make-­‐believe	  play	  or	  social	  imita/ve	  play	  appropriate	  to	  developmental	  level	  
	  
(C)	  restricted	  repe//ve	  and	  stereotyped	  pa`erns	  of	  behavior,	  interests	  and	  ac/vi/es,	  as	  manifested	  by	  at	  least	  two	  of	  the	  following:	  	  
1.	  encompassing	  preoccupa/on	  with	  one	  or	  more	  stereotyped	  and	  restricted	  pa`erns	  of	  interest	  that	  is	  abnormal	  either	  in	  intensity	  or	  
focus	  
2.	  apparently	  inﬂexible	  adherence	  to	  speciﬁc,	  nonfunc/onal	  rou/nes	  or	  rituals	  
3.	  stereotyped	  and	  repe//ve	  motor	  mannerisms	  (e.g	  hand	  or	  ﬁnger	  ﬂapping	  or	  twis/ng,	  or	  complex	  whole-­‐body	  movements)	  
4.	  persistent	  preoccupa/on	  with	  parts	  of	  objects	  
	  
(II)	  Delays	  or	  abnormal	  func/oning	  in	  at	  least	  one	  of	  the	  following	  areas,	  with	  onset	  prior	  to	  age	  3	  years:	  	  
(A)	  social	  interac/on	  
(B)	  language	  as	  used	  in	  social	  communica/on	  
(C)	  symbolic	  or	  imagina/ve	  play	  
	  
(III)	  The	  disturbance	  is	  not	  be`er	  accounted	  for	  by	  Re`'s	  Disorder	  or	  Childhood	  Disintegra/ve	  Disorder	  
	  
1957	  	  &	  1964	  	  
Albert	  Lasker	  
Clinical	  Medical	  Research	  Award	  
	  
Nathan	  Kline	  
	  
1957	  -­‐	  For	  his	  demonstra/ons	  of	  the	  value	  of	  Rauwolﬁa	  
deriva/ves,	  especially	  reserpine,	  in	  the	  treatment	  of	  
mental	  and	  nervous	  disorders.	  
	  
1964	  -­‐	  For	  the	  introduc/on	  and	  use	  of	  iproniazid	  in	  the	  
treatment	  of	  severe	  depression.	  
1987	  Albert	  Lasker	  
Clinical	  Medical	  Research	  Award	  
	  
Mogens	  Schou	  
	  
For	  his	  landmark	  systema/c	  clinical	  trials	  of	  lithium	  as	  therapy	  
and	  prophylaxis	  for	  manic	  depressive	  illness,	  which	  ini/ated	  a	  
revolu/on	  in	  the	  treatment	  of	  mental	  disease.	  
	  
1988	  Albert	  Lasker	  
Clinical	  Medical	  Research	  Award	  
Vincent	  Dole	  
	  
For	  postula/ng	  the	  physiological	  basis	  of	  narco/c	  addic/on	  and	  
for	  developing	  methadone	  treatment	  for	  heroin	  addic/on.	  
2006	  Albert	  Lasker	  
Clinical	  Medical	  Research	  Award	  
	  
Aaron	  Beck	  
	  
For	  the	  development	  of	  cogni/ve	  therapy,	  which	  has	  
transformed	  the	  understanding	  and	  treatment	  of	  many	  
psychiatric	  condi/ons,	  including	  depression,	  suicidal	  behavior,	  
generalized	  anxiety,	  panic	  a`acks,	  and	  ea/ng	  disorders.	  
	  
Medica/ons	  commonly	  used	  for	  au/sm,	  mental	  
retarda/on	  and/or	  aggression	  
•  clonidine	  
•  guanfacine	  
•  risperidone	  
•  haloperidol	  
•  que/apine	  
•  aripiprazole	  
•  lithium	  
•  valproic	  acid	  
•  methylphenidate	  
•  amphetamines	  
•  ﬂuoxe/ne	  
•  citalopram	  
•  Trazodone	  
•  benzodiazepines	  
Infrequently	  used-­‐	  	  
•  chlorpromazine	  
•  clozapine	  
•  other	  SSRIs,	  SSIs,	  or	  TCAs.	  
	  
admission, he was noted to be oriented to name, place, and
time, but no other cognitive testing was done at that time.
Hospital Course
Upon admission, T. displayed mood instability, poor judg-
ment, and verbal and physical threats to harm peers and
staff. He was extremely assaultive and aggressive. He was
unable to use words to express his feelings, which resulted
in him spitting, biting, kicking, cursing, and hitting during
times of crisis. He was placed on constant observation (1:1)
upon admission due to the severity of his aggression. He re-
ported occasional nightmares, was described as hypervigi-
lant around all staff, and occasionally had early insomnia.
Medical workup, including physical exam, blood
chemistries, neurological examination, and an MRI of the
spine were within normal limits.
T. remained aggressive in the hospital for many months
(Fig. 1). His treatment consisted of behavioral and pharma-
cologic intervention used in combination. Over the final five
months of hospitalization, the patient showed remarkable
improvements, with less overall number of incidents and
with less violence in each episode (Fig. 1).
There was never a time during this greater !8-month hos-
pitalization in which there was any evidence of a bipolar or
any psychotic disorder. During his time in the hospital, the
patient did not display sexually inappropriate or fire-setting
behaviors.
Pharmacological Management
After admission, T. was gradually tapered off of risperi-
done 3 mg, clozapine 200 mg, and valproic acid 750 mg. A
trial of lithium was started but discontinued after anger and
behavioral problems notably increased. He was initially
given chlorpromazine only on an as-needed basis, with doses
ranging from 25–100 mg by mouth (PO) or intramuscular
(IM), usually given once or twice per week. Other medica-
tions included diphenhydramine 100 mg PO or 25 mg IM
and risperidone M tabs 1 mg PO as needed. These were given
also 1–2 times per week during the first several months.
Standing doses of chlorpromazine were added, initially 25
mg three times daily (tid) and increased to 50 mg four times
daily, which caused substantial sedation. Later, chlorpro-
mazine was lowered, and sertraline was begun to target the
aggression (Siegel et al. 2007). Sertraline was titrated up
slowly to a total dose of 125 mg daily.
Notably, despite a childhood diagnosis of ADHD, T. had
never had a trial of stimulants, as far as could be determined
from available records and from grandparents. A trial of im-
mediate-release methylphenidate was started and titrated up
to 15 mg PO tid with no adverse effects. There was a dra-
matic improvement in his attention, concentration, and hy-
peractivity. Guanfacine (titrated up to a total dose of 2 mg
daily) was added to address residual impulsivity and irri-
tability, which also was beneficial in controlling this behav-
ior. Towards the end of T.’s hospital course, in order to sim-
plify his medication regimen, the immediate release
methylphenidate was changed to extended release Concerta
54 mg daily, which he also tolerated well. 
During tapering of the chlorpromazine, T. was noted to
have some pill-rolling, shoulder shrugging, and stiff gait,
which was felt to be due to withdrawal dyskinesia. Given
the extrapyramidal symptoms and emergence of a possible
withdrawal dyskinesia, it was decided to slow the taper of
chlorpromazine, and he was discharged on a very small dose
of chlorpromazine. Desmopressin was given for enuresis
with resolution of symptoms.
During the hospitalization, T.’s height increased from five
feet two inches to five feet four and one half inches, and his
weight increased slightly from 134.5 lbs to 137 lbs.
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FIG. 1. Number of incidents including crisis team interventions (calls overhead for assistance), manual restraints, and ur-
gent medications (by mouth or intramuscular) for each month during the course of this patient’s hospitalization.
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Chief Complaint and Presenting Problem
T., A 12-YEAR-OLD Hispanic boy, was transferred to a statechildren’s psychiatric hospital for management of “be-
havioral problems.” He admitted to getting angry and break-
ing things and complained of insomnia, nightmares, and fre-
quent nervousness.
History of Present Illness
T. was reported to have a long history of aggressive, as-
saultive, and unpredictable behavior, angry and irritable
moods, impulsivity, hyperactivity, enuresis, and a history of
nightmares and flashbacks. T. had experienced four prior
psychiatric hospitalizations. Prior to the current transfer,
during an approximately three-month stay at a private hos-
pital, T. was reported to have become increasingly aggres-
sive, assaultive, and impulsive, requiring frequent as-needed
medications including intramuscular injections of lo-
razepam, haloperidol, and chlorpromazine. Lorazepam and
other benzodiazepines were thought to cause disinhibition
and worsened his behaviors. Upon transfer to the state chil-
dren’s psychiatric hospital, T. carried diagnoses of mixed
bipolar disorder, thyroid abnormalities, asthma, and possi-
ble fetal alcohol syndrome.
Upon transfer, T.’s medications included risperidone 3 mg,
clozapine 200 mg, valproic acid 750 mg, guanfacine 4 mg, and
desmopressin 0.6 mg. His as-needed medications were chlor-
promazine 50 mg every two hours, with a maximum of four
doses daily, Benadryl 50 mg every four hours, and albuterol
inhaler two puffs every four hours with a maximum of four
doses daily. The clozapine dose had been adjusted downward
in the previous hospital due to sedation and drooling.
Past Psychiatric History
T. had been hospitalized four times, at ages 6, 7, 8 and 12;
each lasted 1–3 months. The last hospitalization led to trans-
fer to the current state hospital. From age 7 to the present,
T. lived primarily in foster care or at a residential treatment
center when he was not in the hospital. Prior diagnoses given
on discharge summaries included intermittent explosive dis-
order, oppositional defiant disorder, rule-out bipolar mood
disorder not otherwise specified (NOS), and rule-out con-
duct disorder. It was noted that hospitalizations were usu-
ally triggered when foster or group home parents went on
vacation or when T. had a rare visitation with his biological
mother.
T. was first hospitalized at age 6 for increasing aggression
and reportedly smearing feces and fondling his younger sib-
ling. He was also noted to have no friends and to frequently
threaten to kill himself when limits were set. There were also
sexualized behaviors towards his younger stepbrothers; his
father and stepmother described him as “never happy,”
stealing food and money, lying when caught, and hoarding
food. He was also fascinated by guns and violence. All of the
above led to suspicion of neglect and physical and/or sex-
ual abuse of T. at an earlier age. T.’s parents requested out
of home placement for him at age 7 for many reasons, in-
cluding fear for the safety of the other children, and he was
placed in therapeutic foster care.
T.’s second hospitalization occurred at age 7 due to an in-
crease in aggressive behavior. He also reported experiencing
command auditory hallucinations telling him to hurt people.
His thinking was disorganized, characterized by strained
reasoning, poor judgment, and suspicion. It was noted that
he often misinterpreted is environment a d his interaction
with others, and preferred to isolate himself from his peers.
After about two weeks of medication adjustments, thera-
peutic milieu, and individual therapy, he began to show im-
provement in his ability to resist assaulting others. His di-
agnosis at discharge was psychotic disorder, NOS.
The third hospitalization occurred at age 8, also for acting
out and aggressive behavior, although the treatment records
were unavailable from this hospitalization. He was appar-
ently discharged to a residential treatment center at the end
of this hospitalization.
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Chief Complaint and Presenting Problem
T., A 12-YEAR-OLD Hispanic boy, was transferred to a statechildr n’s psychiatric hospital for management of “be-
havioral problems.” He admitted to getting angry and break-
ing t ings and compl i ed of i somnia, nightmares, and f e-
quent nervousn s .
History of Present Illness
T. was reported to have a long history of aggressive, as-
saultive, and unpredictable behavior, angry and irritable
moods, impulsivity, hyperactivity, enuresis, and a history of
nightmares and flashbacks. T. had experienced four prior
psychiatric hospitalizations. Prior to the current transfer,
during an approximately three-month stay at a private hos-
pital, T. was reported to have become increasingly aggres-
sive, assaultive, and impulsive, requiring frequent as-needed
medications including intramuscular injections of lo-
razepam, haloperidol, and chlorpromazine. Lorazepam and
other benzodiazepines were thought to cause disinhibition
and worsened his behaviors. Upon transfer to the state chil-
dren’s psychiatric hospital, T. carried diagnoses of mixed
bipolar disorder, thyroid abnormalities, asthma, and possi-
ble fetal alcohol syndrome.
Upon transfer, T.’s medications included risperidone 3 mg,
clozapine 200 mg, valproic acid 750 mg, guanfacine 4 mg, and
desmopressin 0.6 mg. His as-needed medications were chlor-
promazine 50 mg every two hours, with a maximum of four
doses daily, Benadryl 50 mg every four hours, and albuterol
inhaler two puffs every four hours with a maximum of four
doses daily. The clozapine dose had been adjusted downward
in the previous hospital due to sedation and drooling.
Past Psychiatric History
T. had been hospitalized four times, at ages 6, 7, 8 and 12;
each lasted 1–3 months. The last hospitalization led to trans-
fer to the current state hospital. From age 7 to the present,
T. lived primarily in foster care or at a residential treatment
center when he was not in the hospital. Prior diagnoses given
on discharge summaries included intermittent explosive dis-
order, oppositional defiant disorder, rule-out bipolar mood
disorder not otherwise specified (NOS), and rule-out con-
duct disorder. It was noted that hospitalizations were usu-
ally triggered when foster or group home parents went on
vacation or when T. had a rare visitation with his biological
mother.
T. was first hospitalized at age 6 for increasing aggression
and reportedly smearing feces and fondling his younger sib-
ling. He was also noted to have no friends and to frequently
threaten to kill himself when limits were set. There were also
sexualized behaviors towards his younger stepbrothers; his
father and stepmother described him as “never happy,”
stealing food and money, lying when caught, and hoarding
food. He was also fascinated by guns and violence. All of the
above led to suspicion of neglect and physical and/or sex-
ual abuse of T. at an earlier age. T.’s parents requested out
of home placement for him at age 7 for many reasons, in-
cluding fear for the safety of the other children, and he was
placed in therapeutic foster care.
T.’s second hospitalization occurred at age 7 due to an in-
crease in aggressive behavior. He also reported experiencing
command auditory hallucinations telling him to hurt people.
His thinking was disorganized, characterized by strained
reasoning, poor judgment, and suspicion. It was noted that
he often misinterpreted his environment and his interaction
with others, and preferred to isolate himself from his peers.
After about two weeks of medication adjustments, thera-
peutic milieu, and individual therapy, he began to show im-
provement in his ability to resist assaulting others. His di-
agnosis at discharge was psychotic disorder, NOS.
The third hospitalization occurred at age 8, also for acting
out and aggressive behavior, although the treatment records
were unavailable from this hospitalization. He was appar-
ently discharged to a residential treatment center at the end
of this hospitalization.
“We	  don’t	  have	  to	  look	  for	  a	  model	  
organism	  anymore,	  because	  we	  are	  
the	  model	  organisms.”	  
	  
–	  Sydney	  Brenner,	  Nobel	  Laureate,	  
quote	  in	  2008	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Understanding the spectrum of allelic variation in human genes and 
revealing the demographic and evolutionary forces that shape this varia-
tion within and among populations is a major aim of human genetics 
research. Such information is critical for defining the architecture of 
common diseases, identifying functionally important variation, and ulti-
mately facilitating the interpretation of personalized disease risk profiles 
(1–3). To date, surveys of human variation have been dominated by 
studies of single nucleotide polymorphisms (SNPs) genotyped using 
high-density arrays composed of common variants (4–6). While these 
projects have substantially improved our knowledge of common allelic 
variation and enabled genome-wide association studies (GWAS), they 
have been generally uninformative about the population genetics charac-
teristics of rare variants, defined here as a minor allele frequency (MAF) 
of less than 0.5%. 
Rare genetic variants are predicted to vastly outnumber common 
variants in the human genome (7, 8). By capturing and sequencing all 
protein-coding exons (i.e., the exome, which comprises ~1-2% of the 
human genome), exome sequencing is a powerful approach for discover-
ing rare variation and has facilitated 
the genetic dissection of unsolved 
Mendelian disorders and studying 
human evolutionary history (9–14). 
Rare and low frequency (MAF be-
tween 0.5%-1%) variants have been 
hypothesized to explain a substantial 
fraction of the heritability of common, 
complex diseases (15). Since common 
variants explain only a modest fraction 
of the heritability of most traits (16, 
17), NHLBI recently sponsored the 
multicenter Exome Sequencing Project 
(ESP), to identify novel genes and 
molecular mechanisms underlying 
complex heart, lung, and blood disor-
ders by sequencing the exomes of a 
large number of individuals measured 
for phenotypic traits of substantial 
public health significance (e.g., early-
onset myocardial infarction, stroke, 
body mass index). 
Data generation and variant dis-
covery. A total of 63.4 terabases of 
DNA sequence was generated at two 
centers with three complimentary defi-
nitions of the exome target and two 
different capture technologies (18). We 
sequenced samples from 14 different 
cohorts in the ESP to an average medi-
an depth of 111x (range 23x – 474x). 
We found no evidence of cohort- 
and/or phenotype specific effects, or 
other systematic biases, in the analysis 
of the filtered SNV data (18; Figs. S1-
S7). Exomes from related individuals 
were excluded from further analysis 
(18; Fig. S8) resulting in a dataset of 
2,440 exomes. We inferred genetic 
ancestry using a clustering approach 
(18), and focused the remaining anal-
yses on the inferred 1,351 EA and 
1,088 AA individuals. We subjected 
the 563,698 variants in the intersection 
of all three capture targets to standard 
quality control filters (18) resulting in a final data set of 503,481 single 
nucleotide variants (SNVs) identified in 15,585 genes and 22.38 Mb of 
targeted sequence per individual. We assessed data quality and error 
rates using complementary strategies (18). Approximately 98% 
(941/961) of all variant sites that were experimentally tested were con-
firmed, including 98% (234/238) of singletons, 98% (678/693) of non-
singleton SNV sites with a MAF < 10%, and 97% (29/30) of SNV sites 
ZLWKD0$) 
The vast majority of coding variation is rare and novel. We ob-
served a total of 503,481 SNVs and 117 fixed, non-reference sites, of 
which 325,843 and 268,903 were found in AA and EA, respectively (18; 
Fig. S9A). Excluding singletons, ~58% of SNVs were population-
specific (93,278 and 32,552 variants were uniquely observed in AA, or 
EA, respectively), and the vast majority of these variants were rare (18; 
Fig. S9B). Most SNVs (292,125 or 58%) were nonsynonymous includ-
ing 285,960 missense variants and 6,165 nonsense variants (18; Fig. 
S9C). Synonymous variants accounted for 38% (188,975) of the total 
SNVs (18; Fig. S9C), with the remaining 4% of SNVs (22,381) located 
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As a first step toward understanding how rare variants contribute to risk for 
complex diseases, we sequenced 15,585 human protein-coding genes to an average 
median depth of 111x in 2,440 individuals of European (n=1,351) and African 
(n=1,088) ancestry. We identified >500,000 single nucleotide variants (SNVs), the 
majority of which were rare (86% with a minor allele frequency < 0.5%), novel (82%), 
and population-specific (82%). On average, 2.3% of the 13,595 SNVs each person 
carries were predicted to impact protein function of ~313 genes per genome, and 
~95.7% of SNVs predicted to be functionally important were rare. This excess of rare 
functional variants is due to the combined effects of explosive, recent accelerated 
population growth and weak purifying selection. Furthermore, we show that large 
sample sizes will be required to associate rare variants with complex traits. 
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Crohn’s disease and ulcerative colitis are classified as chronic, idi-
opathic inflammatory bowel diseases (IBDs) of the gastrointestinal 
tract with unknown etiology (MIM266600). Crohn’s disease occurs 
in about 100–150 per 100,000 individuals of European a cestry1. 
Generally, the disease affects the ileum and colon, but it can affect any 
region of the gut. Ulcerative colitis has similar population prevalence, 
and although it has some similarities to Crohn’s disease in clinical 
manifestation, the location of inflammation is limited to the colonic 
mucosa. Strong familial aggregation has been observed in twin studies 
of Crohn’s disease and ulcerative colitis2,3. Recent population-based 
sibling risk is 26-fold greater for Crohn’s diseas  and 9-fold greater for 
ulcerative colitis2, and overall Crohn’s disease and ulcerative colitis 
concordance rates in nonselected twin studies are 30% and 15%, 
respectively, among monozygotic twins compared with 4% for 
Crohn’s disease or ulcerative colitis among dizygotic twins3. Like most 
complex diseases, Crohn’s disease and lcerative colitis result from 
a combination of genetic and nongenetic risk factors, and each 
individual factor probably has a modest effect on disease risk4.
Deep resequencing of GWAS loci identifies independent 
rare variants associated with inflammatory bowel disease
Manuel A Rivas1–3, Mélissa Beaudoin4,23, Agnes Gardet5,23, Christine Stevens2,23, Yashoda Sharma6,  
Clarence K Zhang6, Gabrielle Boucher4, Stephan Ripke1,2, David Ellinghaus7, Noel Burtt2, Tim Fennell2,  
Andrew Kirby1,2, Anna Latiano8, Philippe Goyette4, Todd Green2, Jonas Halfvarson9, Talin Haritunians10,  
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Mauro D’Amato21, Dermot P B McGovern10,22, Judy H Cho6, John D Rioux4, Ramnik J Xavier1,2,5 & Mark J Daly1,2
More than 1,000 susceptibility loci have been identified through genome-wide association studies (GWAS) of common variants; 
however, the specific genes and full allelic spectrum of causal variants underlying these findings have not yet been defined. Here 
we used pooled next-generation sequencing to study 56 genes from regions associated with Crohn’s disease in 350 cases and 350 
controls. Through follow-up genotyping of 70 rare and low-frequency protein-altering variants in nine independent case-control 
series (16,054 Crohn’s disease cases, 12,153 ulcerative colitis cases and 17,575 healthy controls), we identified four additional 
independent risk factors in NOD2, two additional protective variants in IL23R, a highly significant associa i n with a protective 
splice varia t in CARD9 (P < 1 × 10−16, odds ratio y 0.29) and additional associations with coding variants in IL18RAP, CUL2, 
C1orf106, PTPN22 and MUC19. We extend the results of successful GWAS by identifying new, rare and probably functional 
variants that could aid functional experiments and predictive models.
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SUMMARY
While it is known that rare copy-number variants
(CNVs) contribute to risk for some neuropsyc iatric
disorders, the role of CNVs in bipolar disorder is
unclear. Here, we reasoned that a contribution of
CNVs to mood disorders might be most evident for
de novo mutations. We performed a genome-wide
an lysis of de novo CNVs in a cohort of 788 rios.
Diagnoses of offspring included bipolar disorder
(n = 185), schizophre ia ( = 177), and healthy
controls (n = 426). Frequencies of de novo CNVs
were significantly higher in bipolar disorder as com-
pared with controls (OR = 4.8 [1.4,16.0], p = 0.009).
De novo CNVs were particularly enriched among
cases with an age at onset younger than 18 (OR =
6.3 [1.7,22.6], p = 0.006). We also confirmed a signifi-
cant enrichment of de novo CNVs in schizophrenia
(OR = 5.0 [1.5,16.8], p = 0.007). Our results suggest
that rare spontaneous mutations are an important
contributor to risk for bipolar diso der and other
major neurop ychiatric diseases.
INTRODUCTION
Bipolar disorder (BD, also known s a ic-depressive illness) is
a severe ood disord r onsisti g of episodes of mania and
epression. The lifetime prevalence of bipolar disorder in the
gen ral population is !1% and the illness i associated with
consid rable morbidity and a high lif time isk of suicide (Meri-
kangas et al., 2011).
Genes play an important r le in risk for BD. Th rate of concor-
dance formonozygotic twins is 40%, comparedwith a 5% rate in
dizygotic twins (Kendler et al., 1995; Kieseppa¨ et al., 2004;
McGuffin et al., 2003), and risk among the first-degree relatives
of individuals with BD is ten-fold greater than risk among the
general population (Barnett and Smoller, 2009). However, as
with other psychiatric disorders, the genetics of BD is complex,
Neuron 72, 951–963, December 22, 2011 ª2011 Elsevier Inc. 951
Rare	  Variants	  –	  CNVs,	  SNVs,	  indels,	  etc…	  in	  Rare	  AND	  Common	  diseases	  
Some	  Deﬁni/ons	  …	  
•  The	  words	  “penetrance”	  and	  “expressivity”,	  deﬁned	  
classically	  as:	  
•  Penetrance:	  whether	  someone	  has	  ANY	  symptoms	  of	  a	  
disease,	  i.e.	  all	  or	  none,	  0%	  or	  100%.	  Nothing	  in	  between.	  
•  Expressivity:	  how	  much	  disease	  (or	  how	  many	  symptoms)	  
someone	  with	  100%	  penetrance	  has.	  
•  This	  has	  led	  to	  endless	  confusion!	  	  
•  Some	  just	  use	  the	  word	  “penetrance”	  to	  mean	  the	  
expressivity	  of	  disease,	  i.e.	  incomplete	  penetrance,	  and	  
maybe	  we	  should	  combine	  the	  two	  terms	  into	  ONE	  word	  
with	  the	  full	  expression	  from	  0-­‐100%	  of	  phenotypic	  
spectrum.	  
Deﬁni(ons.	  It	  is	  unknown	  what	  
por/on	  of	  au/sm	  will	  be	  oligogenic	  vs.	  
polygenic	  
•  Oligogenic	  –	  mul/ple	  muta/ons	  together	  
contribu/ng	  to	  aggregate	  disease,	  BUT	  with	  only	  
1	  muta/on	  of	  ~	  >10%	  penetrance	  (or	  “eﬀect	  size)	  
in	  EACH	  person.	  
•  Polygenic	  –	  Dozens	  to	  hundreds	  of	  muta/ons	  in	  
diﬀerent	  genes	  in	  the	  SAME	  person,	  together	  
contribu/ng	  to	  the	  disease	  in	  the	  SAME	  person,	  
hence	  addi(ve	  and/or	  epista(c	  contribu/on	  with	  
~0.01-­‐1%	  penetrance	  for	  each	  muta/on.	  
	  “Of	  complex	  gene/c	  diseases,	  schizophrenia	  has	  perhaps	  
been	  the	  subject	  of	  the	  most	  specula/on	  and	  debate	  
rela/ng	  to	  its	  gene/c	  architecture4,5,	  and	  the	  rela/ve	  
importance	  of	  common	  causal	  variants	  remains	  
controversial6,7.”	  
Example	  of	  Polygenic	  Model	  
Visscher	  et	  al.	  2011	  
Penetrance	  Issues	  
•  We	  do	  not	  really	  know	  the	  penetrance	  of	  	  pre`y	  much	  
ALL	  muta/ons	  in	  humans,	  as	  we	  have	  not	  
systema/cally	  sequenced	  or	  karyotyped	  any	  gene/c	  
altera/on	  in	  Thousands	  to	  Millions	  of	  randomly	  
selected	  people,	  nor	  categorized	  into	  ethnic	  classes,	  
i.e.	  clans.	  
•  There	  is	  a	  MAJOR	  clash	  of	  world-­‐views,	  i.e.	  do	  single	  
muta/ons	  drive	  outcome	  predominately,	  or	  are	  the	  
results	  modiﬁed	  substan/ally	  by	  gene/c	  background	  
and/or	  environment?	  i.e.	  is	  there	  really	  such	  a	  thing	  as	  
gene/c	  determinism	  for	  MANY	  muta/ons?	  
“Biological	  Indeterminacy”	  
•  Bateson	  became	  famous	  as	  the	  outspoken	  
Mendelian	  antagonist	  of	  Walter	  Raphael	  Weldon,	  
his	  former	  teacher,	  and	  Karl	  Pearson	  who	  led	  the	  
biometric	  school	  of	  thinking.	  This	  concerned	  the	  
debate	  over	  salta/onism	  versus	  gradualism	  
(Darwin	  had	  been	  a	  gradualist,	  but	  Bateson	  was	  a	  
salta/onist).	  Later,	  Ronald	  Fisher	  and	  
J.B.S.	  Haldane	  showed	  that	  discrete	  muta/ons	  
were	  compa/ble	  with	  gradual	  evolu/on:	  see	  the	  
modern	  evolu/onary	  synthesis.	  
Biological	  Indeterminacy.	  Greenspan	  RJ.	  Sci	  Eng	  
Ethics.	  2012	  Jul	  3	  
	  
Beyond	  our	  Kuhnian	  inheritance	  
A	  recent	  lecture	  by	  Prof	  Greg	  Radick	  ques/ons	  our	  scien/ﬁc	  inheritance,	  
through	  textbook	  histories	  of	  gene/cs	  and	  Thomas	  Kuhn's	  legacy	  
h`p://www.guardian.co.uk/science/the-­‐h-­‐word/2012/aug/28/thomas-­‐
kuhn	  
Walter	  Frank	  Raphael	  Weldon	  
Vs.	  	  
William	  Bateson	  
Forthcoming	  by	  Greg	  Radick.	  Scholarly	  edi/on	  of	  W.	  F.	  R.	  Weldon's	  Theory	  of	  
Inheritance	  (1904-­‐1905),	  coedited	  with	  Annie	  Jamieson.	  
Waddington	  claimed	  that	  canals	  form	  in	  the	  epigene(c	  
landscape	  during	  evolu(on,	  and	  that	  this	  heuris(c	  is	  useful	  for	  
understanding	  the	  unique	  quali(es	  of	  biological	  robustness.	  
The	  canalisa/on	  metaphor	  suggests	  that	  phenotypes	  are	  very	  robust	  to	  small	  perturba/ons,	  
for	  which	  development	  does	  not	  exit	  the	  canal,	  and	  rapidly	  returns	  back	  down,	  with	  li`le	  
eﬀect	  on	  the	  ﬁnal	  outcome	  of	  development.	  But	  perturba/ons	  whose	  magnitude	  exceeds	  a	  
certain	  threshold	  will	  break	  out	  of	  the	  canal,	  moving	  the	  developmental	  process	  into	  
uncharted	  territory.	  Strong	  robustness	  up	  to	  a	  limit,	  with	  li`le	  robustness	  beyond,	  is	  a	  pa`ern	  
that	  could	  increase	  evolvability	  in	  a	  ﬂuctua/ng	  environment.	  
The	  gene/c	  basis	  of	  a	  new	  syndrome	  
with	  severe	  developmental	  delay	  and	  
cardiac	  abnormali/es.	  
Family	  now	  in	  October	  2011,	  with	  ﬁve	  muta(on-­‐
posi(ve	  boys	  dying	  from	  the	  disease.	  
I
II 
III 
1 +/ 2 +/mt 
1 mt/ 
1
2 +/mt 
2 +/ 3 +/+ 4 mt/ 
3  +/mt 
5 7 mt/ 
4 5 +/mt 6 7 +/+ 8 +/ 
SB 
6 mt/ 

Published	  in	  “Biology	  of	  Mental	  Defect”,	  by	  Lionel	  Penrose,	  1949	  
And	  “John	  Langdon	  Down:	  A	  Caring	  Pioneer”,	  by	  O	  Conor	  Ward,	  1998.	  
Published	  in	  “John	  Langdon	  Down:	  A	  Caring	  Pioneer”,	  by	  O	  Conor	  Ward,	  1998.	  
Published	  in	  “John	  Langdon	  Down:	  A	  Caring	  Pioneer”,	  by	  O	  Conor	  Ward,	  1998.	  

Down	  Syndrome	  
Down	  Syndrome	  
Christopher	  Joseph	  "Chris"	  Burke	  (born	  August	  
26,	  1965)	  is	  an	  American	  actor	  and	  folk	  singer,	  
who	  lives	  with	  Down	  syndrome,	  who	  has	  
become	  best	  known	  for	  his	  character	  Charles	  
"Corky"	  Thacher	  on	  the	  television	  series	  Life	  
Goes	  On.	  
	  
And	  there	  are	  people	  with	  Mosaic	  Down	  
Syndrome,	  who	  are	  much	  less	  aﬀected.	  
Velocardiofacial	  (22q11.2)	  Syndrome	  
16p11.2 deletion 
Fernandez B A et al. J Med Genet 2010;47:195-203 
©2010 by BMJ Publishing Group Ltd 
Clinical photographs. (a and b) Proband 2 (de novo deletion 16p11.2). Note long 
narrow palpebral fissures, short delicate nose, short neck and brachydactyly with 
2–3 cutaneous toe syndactyly. (c and d) Mother of proband 3 (both with 
deletions). Note her large ears, smooth philtrum and short fifth toes. 	  
16p11.2 duplication 
Fernandez B A et al. J Med Genet 2010;47:195-203 
©2010 by BMJ Publishing Group Ltd 
Clinical photographs. (e) Proband 5 who has a maternally inherited 
duplication. (f) Proband 5 (note smooth philtrum) and her healthy duplication 
positive sister. (g) Duplication positive mother of proband 5, who also has a 
smooth philtrum. (h) Proband 6 (inherited duplication and oliogohydramnios 
sequence). Note her frontal bossing, receding hairline, hypoplastic 
supraorbital ridges and smooth philtrum. (i) Proband 6's right hand showing 
fifth finger clinodactyly. 	  
16p11.2	  dele/on,	  not	  in	  mother	  or	  
father,	  only	  in	  child.	  	  
5	  years	  old,	  but	  developmental	  
age	  of	  2	  year	  old.	  
Speaks	  a	  few	  words,	  almost	  
unintelligible.	  
Very	  hyperac/ve.	  
Can	  be	  withdrawn	  and	  has	  at	  
/mes	  been	  diagnosed	  with	  
“au/sm”.	  
*Private	  Photograph	  –	  Do	  not	  further	  distribute.	  

Master	  Craysman	  
Most	  famously	  designed	  The	  Great	  
Eastern,	  a	  10	  foot	  long	  model	  ship	  
with	  incredible	  detail.	  
	  
Deaf	  and	  nearly	  mute	  –	  Nonverbal,	  
Obsessed	  with	  one	  topic	  of	  
building	  things.	  
Thought	  to	  be	  mentally	  retarded.	  
Usually	  quiet	  and	  reserved,	  but	  
some/mes	  was	  intolerant	  of	  
advice,	  suspicious	  of	  strangers,	  and	  
ill-­‐tempered	  and	  violent.	  
“The	  clinical	  and	  pathological	  
evidence	  of	  a	  pervasive	  
developmental	  disorder	  points	  to	  a	  
retrospec/ve	  diagnosis	  of	  au/sm.”	  
Historical 
The Victorian genius of Earlswood - a 
review of the case of James Henry Pullen 
Caoimhghin S Breathnach, Conor Ward 
Summary 
London born James Henry Pullen (1836-1915) was 
admitted to Essex Hall in Colchester, an institution catering 
for learning disability, at the age of 13. Here his artistic 
talent was spotted before he moved two years later to 
Earlswood Asylum for Idiots, where he was apprenticed to 
woodworking. Such was his manual skill he was eventually 
employed making furniture for the asylum. His artistic 
propensity was similarly encouraged and although he never 
mastered coherent speech he has left a pictorial 
autobiography of some distinction. At observation he 
underwent detailed examination by Frederich Sano (1871-
1946), particular attention being paid to tokens of arrested 
development. The clinical and pathological evidence of a 
pervasive developmental disorder points to a retrospective 
diagnosis of autism. 
Key words: History; Autism; Victorian genius; Learning 
disability; Developmental disorder. 
Introduction 
In 1870 Sequin described children who had 'a useless 
protrusion of a single faculty accompanied by a woeful 
general impotence'.' Langdon Down introduced the term 
idiots savants to describe them.' The first idiot savant recog-
nised in England was Jedediah Buxton, an illiterate 
Derbyshire farmhand who could multiply two 39 digit 
numbers.3 Of the seven cases described by Langdon Down, 
the best known was James Henry Pullen, known colloquially 
as the Genius of Earlswood. Langdon Down's identification 
of the syndrome had previously been referred to in 1865.' 
Clinical history 
Pullen's parents were first cousins. They lived in Peckham 
in south London. Of 13 children six died in infancy and only 
three survived into adult life.' His brother William too, also 
cared for in an institution, had exceptional artistic skills. James 
Henry combined primitive speech with sign language. He 
could not write in coherent sentences, but he drew over 80 
sketches illustrating his life. These present a unique life story. 
Boats fascinated him from an early age. Wearing skirts, and 
not yet in breeches, he is seen at the age of nine years 
making a crude model ship from a wooden box. (Figure 1, left 
*Caoimhghin 5 Breathnach, MD, PhD, 
Con or Ward, MD, PhD, FRCPl, Departments of Anatomy & 
Physiology, Paediatrics and Maurice Kennedy Research Centre 
for Emeritus Staff, NUl University College Dublin, Ireland. 
*Correspondence 
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pane1. Boys usually graduated to wearing breeches at the 
age of six years. Assuming that he inscribed the correct date 
his being still unbreeched at this late age suggests that he 
was seen in the family to have failed to reach an appropriate 
developmental age. The next year he watches an adult, 
maybe his father, sailing a crude three-masted sailing ship -
possibly his improved design- in a pond (Figure 1, middle 
pane1. When he was 12 he visited London. To him it was not 
a city of roads and shops and carriages but a great waterway 
alive with sailing activity (Figure 1, right pane1. In 1901 his 
sister, Mrs Earwicker, set out her memory of his early life. His 
first word was 'muvver'. No school would take him because 
he seemed to be unable to learn. He spent his time at home 
making ships from firewood, cotton and pins. In 1848, aged 
13, he was admitted to Essex Hall in Colchester, an institu-
tion catering for learning disability.' 
Essex Hall which later became the Royal Eastern Counties 
Asylum, was a charity set up by Rev Andrew Reed. It was 
here that his artistic talent was uncovered. In his pictorial 
autobiography he shows himself in 1848 drawing at a school 
table. There is no other young person in the picture, suggest-
ing that he was being taught on his own outside school hours 
(Figure 2, left pane1. The time on the clock is 1.45, school 
finished at 1.00. On this assumption the benign female pres-
ence is likely to be that of Mrs Sarah Pearce, identified in the 
Census of 1851 as the 38-year-old schoolmistress. Was it 
she who opened up new artistic horizons for him? The follow-
ing year, by which time he had learned to write his surname, 
he went on the Essex Hall outing to Walton-on-the-Naze. He 
portrayed a man leading the way towards the harbour. The 
masts of a ship stand out over the promenade wall. Mrs 
Pearce's husband Henry, a porter aged 40, may have been 
his guide. 
In 1850 James was moved to the Earlswood Asylum for 
Idiots, another institution set up by Andrew Reed. The Essex 
Hall educational programme had been very progressive,' and 
the young man portrays himself looking sadly back at Essex 
Hall and at his collection of 1 2 pictures, three of them depict-
ing boats (Figure 2, middle pane1. The configuration of the 
window does not match the shape of the windows in a 
contemporary sketch of Essex hall, suggesting that his work 
had been put on display in another location. 
He was put into the school at Earlswood, but his self-
portrait of 1851 is of a boy with his head buried in the tearful 
despair of failure (Figure 2, right pane1. By 1852, however, 
he was apprenticed to woodwork and boatmaking, and at his 
second attempt he produced a three-masted ship which he 
thought good enough to present to his teacher as a mark of 
appreciation (Figure 3, left pane1. His apprenticeship to 
woodworking led to the progressive complexity of his model-
ling especially after 1859. John Langdon Down, the newly 
r 
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Sibling	  Defense	  Theory	  
•  Defense	  or	  modiﬁer	  Genes?	  –	  muta/ons	  that	  
somehow	  protect	  against	  or	  modify	  the	  eﬀects	  
of	  a	  primary	  muta/on.	  
•  Or,	  can	  female	  gender	  also	  somehow	  be	  
protec/ve	  with	  certain	  muta/ons?	  
•  Henry	  Pullen	  was	  one	  of	  13	  children,	  but	  only	  
3	  lived	  to	  adult	  life.	  His	  brother,	  William,	  was	  
also	  ins/tu/onalized	  and	  had	  excep/onal	  
ar/s/c	  skills.	  Their	  parents	  were	  ﬁrst	  cousins.	  
=ASD	  
=Odd,	  poten/al	  
broader	  
phenotype	  
=ADHD	  =ASD	  
=Odd,	  poten/al	  
broader	  
phenotype	  
New	  Syndrome	  with	  Mental	  
Retarda/on,	  “Au/sm”,	  “ADHD”	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old
	  	  
Dysmorphic	  
Mental	  Retarda/on	  
“au/sm”	  
“ADHD”	  
Hearing	  diﬃcul/es	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  gene/c	  tests	  nega/ve,	  including	  
nega/ve	  for	  Fragile	  X	  and	  MANY	  candidate	  
genes.	  
•  Found	  one	  missense	  muta/on	  in	  a	  known	  
mental	  retarda/on	  gene,	  but	  the	  muta/on	  is	  a	  
very	  conserva/ve	  nonsynonymous	  Asp	  to	  Glu.	  
Is	  it	  relevant	  or	  not?	  What	  about	  the	  whole	  
rest	  of	  the	  genome?	  
Sequenced	  whole	  genomes	  of	  Mother,	  Father	  
and	  Two	  Boys,	  using	  Complete	  Genomics	  
•  Sequenced	  “whole”	  genomes	  to	  obtain	  noncoding	  and	  
other	  non-­‐exonic	  regions.	  
•  No	  obvious	  pathogenic	  CNVs	  –	  microarrays	  normal.	  
•  ~6	  million	  variants	  total	  in	  the	  4	  people	  diﬀerent	  from	  
Hg19	  reference	  genome.	  
•  No	  homozygous	  autosomal	  recessive	  muta/ons	  found.	  
•  No	  Nonsense/Frameshiy	  muta/ons	  in	  both	  boys.	  
•  2	  muta/ons	  present	  in	  mother	  and	  two	  boys,	  on	  X-­‐
chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  not	  in	  
1000Genomes	  April	  2012	  release,	  and	  not	  in	  NHLBI	  
6500	  Exomes	  
	  
2	  muta/ons	  present	  in	  mother	  and	  two	  boys,	  on	  
X-­‐chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  
not	  in	  1000Genomes	  April	  2012	  release,	  and	  not	  
in	  NHLBI	  6500	  Exomes	  
	  
•  Nonsyn	  SNV	  	  	  ZNF41	  	  	  	  c.1191C>A	  	  p.Asp397Glu	  	  
	  	  
•  Nonsyn	  SNV	  	  	  TAF1	  	  	  	  	  	  	  c.4010T>C	  	  p.Ile1337Thr	  	  
	  
TAF1	  RNA	  polymerase	  II,	  TATA	  box	  binding	  protein	  
(TBP)-­‐associated	  factor,	  250kDa	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Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Menzel,1 Udo Trautmann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
Claude Moraine,6 Jean-Pierre Fryns,7 Jamel Chelly,8 Hans-Dieter Rott,2 Hans-Hilger Ropers,1
and Vera M. Kalscheuer1
1Max-Planck-Institute for Molecular Genetics, Berlin; 2Institute of Human Genetics, University of Erlangen-Nuremberg, Erlangen-Nuremberg;
3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
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electronically published November 18, 2003.
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. Th 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that nu erous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-ch omosomal and the uto omal b eak-
point. In silico sequence analysis provided o indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that t e ntal
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
•  KRAB	  (Kruppel-­‐associated	  box)	  domain	  -­‐A	  box.	  
•  The	  KRAB	  domain	  is	  a	  transcrip/on	  repression	  module,	  found	  
in	  a	  subgroup	  of	  the	  zinc	  ﬁnger	  proteins	  (ZFPs)	  of	  the	  C2H2	  
family,	  KRAB-­‐ZFPs.	  KRAB-­‐ZFPs	  comprise	  the	  largest	  group	  of	  
transcrip/onal	  regulators	  in	  mammals,	  and	  are	  only	  found	  in	  
tetrapods.	  	  
•  The	  KRAB	  domain	  is	  a	  protein-­‐protein	  interac/on	  module	  
which	  represses	  transcrip/on	  through	  recrui/ng	  corepressors.	  
The	  KAP1/	  KRAB-­‐AFP	  complex	  in	  turn	  recruits	  the	  
heterochroma/n	  protein	  1	  (HP1)	  family,	  and	  other	  chroma/n	  
modula/ng	  proteins,	  leading	  to	  transcrip/onal	  repression	  
through	  heterochroma/n	  forma/on.	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Figure 4 A, Pedigree of family P13, with sequence corresponding to the prolinerleucinemutation (left to right): unrelated control individual,
mother (II:1), index patient (III:2), and brother of the index patient (III:1). For the potentially affected female cousin (individual III-4) (indicated
with an asterisk [*]), no clinical data are available. Affected nucleotides are indicated with black arrows. B, Pedigree for family P42, with
sequence chromatograms indicating the splice-site mutation in affected individuals (left to right): father (I:1), mother (I:2), index patient (II:1),
and mildly affected sister (II:2). Uppercase letters indicate coding sequence; affected nucleotides are indicated with black arrows.
a diagnosis of mild MR. He was born at term (by Ce-
sarean section), with a birth weight of 3,000 g (10th–25th
percentile) and a length of 51 cm (50th percentile). He
walked at age 12–13 mo and reached early milestones
within the normal time frame; however, he exhibited a
severe language delay. He first made two-word associa-
tions at age 3 years and was first speaking in simple
phrases at age 4 years 6 mo. At age 8 years, he was 135
cm tall (90th percentile) and had a head circumference
of 53 cm (75th percentile). He had no additional dys-
morphic or neurological symptoms, and results of
screening for fragile X were negative. At age 10 years 3
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Figure 6 Northern blot hybridization of ZNF41, by use of a probe corresponding to nucleotides 621–1099 of ZNF41 transcript variant
1. A, Adult tissues (left to right): heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. B, Fetal tissues (left to right): brain,
lung, liver, and kidney.C,Adult brain structures (left to right): amygdala, caudate nucleus, corpus callosum, hippocampus, whole brain, substantia
nigra, and thalamus. Black arrowheads highlight the presence of a novel 6-kb transcript. Actin (A and C) or GAPDH (B) served as controls
for RNA loading.
sible for sequence-specific DNA binding. ZNF41, absent
in our patient, is a member of the subfamily of Krueppel-
type zinc-finger proteins harboring a highly conservedN-
terminal domain known as the Krueppel-associated box
(KRAB). Although the specific functions of ZNF41 are
not fully understood, various related genes play an es-
tablished and important role in human development and
disease (Ladomery and Dellaire 2002). In another female
patient with severe MRX and a balanced translocation,
the disorder probably resulted from the disruption of a
related X-chromosomal zinc-finger gene (Lossi et al.
2002). The X-chromosome breakpoint was located just
upstream of the Krueppel-like factor 8 (KLF8 [MIM
300286]), also known as the “ZNF741 gene,” and it was
confirmed that KLF8 transcripts were absent in the pa-
tient cell line. The Wilms tumor suppressor gene WT1
(MIM 194070), which harbors four Krueppel-type zinc
fingers, has been implicated in several urogenital devel-
opmental disorders, including WAGR syndrome (MIM
194072), which is associated with MR (Call et al. 1990;
Rose et al. 1990; Gessler et al. 1992). Of particular rel-
evance, however, are the biochemical studies that high-
light the links between the highly conserved KRAB/ZFP
subfamily of zinc-finger proteins and chromatin remod-
eling. Many disorders, several of which are associated
with MR, have been linked to defects in processes that
govern chromatin structural modification (Hendrich and
Bickmore 2001), suggesting that chromatin structural
regulationmay play a specific and important role in path-
ways critical for mental function.
Repression of transcription by a KRAB/ZFP requires
binding of the corepressor KAP-1 (also known as
“TIF1b” and “KRIP-1” [MIM 601742]) (Friedman et
al. 1996; Kim et al. 1996; Moosmann et al. 1996; Peng
et al. 2000a, 2000b). KAP-1 is a molecular scaffold that
coordinates gene-specific silencing by recruiting both
heterochromatin-associated proteins (Ryan et al. 1999)
and by interacting with the novel histone H3 Lys9–
specific methyltransferase SETDB1 (MIM 604396)
(Schultz et al. 2002). It is interesting that, within the
primary sequence of SETDB1, Schultz et al. (2002) iden-
tified a methyl CpG–binding domain that is related to
the domain found in the methyl CpG binding protein
MeCP2, which is mutated both in patients with Rett
syndrome (MIM 312750) (Amir et al. 1999) and in
patients with MRX (Couvert et al. 2001; Yntema et al.
2002). Like ZNF41, MECP2 is ubiquitously expressed;
yet loss of functional protein results in a neurological
phenotype. Although the mechanism by whichMECP2
mutations cause MR is not clear, it is well established
that MeCP2 binds to methylated CpGs and represses
transcription (for review, see Ballestar and Wolffe
[2001]), and it has recently been shown that MeCP2
associates with an unidentified methyltransferase that
specifically methylates Lys9 of histone H3 (Fuks et al.
2003), as does the KAP-1/KRAB/ZFP binding partner
SETDB1.
Further characterization of the KRAB/KAP-1 repres-
sor module has indicated that, in addition to the KRAB
domain, a bipartite domain of the plant homeodomain
(PHD) finger and a bromodomain, located within the C-
terminal portion of KAP-1, are also required for effective
gene silencing (Schultz et al. 2002). It is interesting that
the point mutations in that study were modeled after
naturally occurring mutations in the PHD finger of the
human ATRX gene, which has been implicated in both
X-linked a-thalassemia/MR syndrome (MIM 301040)
(Gibbons et al. 1995) and Juberg-Marsidi syndrome
(MIM 309590), which is also associated with MR (Vil-
lard et al. 1996a). In light of the fact that the PHD
Proving	  Causality	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The duplication architecture of the human genome predisposes our species to recurrent copy number
variation and disease. Emerging data suggest that this mechanism of mutation contributes to both
common and rare diseases. Two features regarding this form of mutation have emerged. First, common
structural polymorphisms create susceptible and protective chromosomal architectures. These structural
polymorphisms occur at varying frequencies in populations, leading to different susceptibility and ethnic
predilection. Second, a subset of rearrangements shows extreme variability in expressivity. We propose
that two types of genomic disorders may be distinguished: syndromic forms where the phenotypic features
are largely invariant and those where the same molecular lesion associates with a diverse set of diagnoses
including epilepsy, schizophrenia, autism, intellectual disability and congenital malformations. Copy number
variation analyses of patient genomes reveal that disease type and severity may be explained by the occur-
rence of additional rare events and their inheritance within families. We propose that the overall burden of
copy number variants creates differing sensitized backgrounds during development leading to different
thresholds and disease outcomes. We suggest that the accumulation of multiple high-penetrant alleles
of low frequency may serve as a more general model for complex genetic diseases, posing a significant
challenge for diagnostics and disease management.
INTRODUCTION
Genomic disorders were originally described as large deletions
and duplications that are highly penetrant, mostly de novo in
origin, and typically identified in affected individuals with intel-
lectual disability/multiple congenital malformations. Some
examples include Smith–Magenis syndrome (MIM: 182290),
DiGeorge/velocardiofacial syndrome (MIM: 188400, 192430)
andWilliams–Beuren syndrome (MIM: 194050). These classi-
cal genomic disorders have been well characterized in the past
two decades with genotype–phenotype correlation studies
implicating causative genes, mouse models recapitulating the
human clinical features, and standardized management proto-
cols and support groups established.
Application of higher definition molecular techniques,
including single-nucleotide polymorphism microarrays or
array comparative genomic hybridization (CGH), has allowed
genotyping of larger disease cohorts and controls. Two major
principles have emerged from these more recent studies: (i)
common copy number polymorphism predisposes certain
chromosomes to recurrent deletions and duplications and
(ii) association of the same recurrent genomic lesion with
apparently very diverse phenotypes. The latter has begun to
illuminate common neurodevelopmental pathways and
helps to explain the comorbidity of diverse neurological
manifestations within the same families. The distinction
between variability of expressivity and reduced penetrance
depending on the diagnosis has become an important consider-
ation for these rare mutational events. We will explore the
mechanisms, models and implications underlying these two
different aspects.
GENOMIC SUSCEPTIBILITY TO RECURRENT
DELETIONS AND DUPLICATIONS
Seminal work on Charcot–Marie–Tooth disease (1,2) and
hereditary neuropathy with liability to pressure palsies
(HNPP) (3) directly implicated low-copy repeats or segmental
duplications as substrates for unequal crossover or non-allelic
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Objective: The authors used a genome-
wide association study (GWAS) of multiply
affected families to investigate the associ-
ation of schizophrenia to common single-
nucleotide polymorphisms (SNPs) and rare
copy number variants (CNVs).
Method: The family sample included
2,461 individuals from 631 pedigrees (581
in the primary European-ancestry analyses).
Association was tested for single SNPs and
genetic pathways. Polygenic scores based
on family study results were used to predict
case-control status in the Schizophrenia
Psychiatric GWAS Consortium (PGC) data
set, and consistency of direction of effect
with the family study was determined for
top SNPs in the PGC GWAS analysis. Within-
family segregation was examined for
schizophrenia- ss ciated rare CNVs.
Results: No genome-wide signiﬁcant asso-
ciationswereobserved for single SNPs or for
pathways. PGC case and control subjects
had signiﬁcantly different genome-wide
polygenic scores (computed by weighting
their genotypes by log-odds ratios from the
family study) (best p=10217, explaining
0.4% of the variance). Family study and
PGC analyses had consistent directions for
37 of the 58 independent best PGC SNPs
(p=0.024). The overall frequency of CNVs
in regions with reported associations
with schizophrenia (chromosomes 1q21.1,
15q13.3, 16p11.2, and 22q11.2 and the
neurexin-1 gene [NRXN1]) was similar to
previou case-control studies. NRXN1
deletions and 16p11.2 duplications (both
of which were transmitted from parents)
and 22q11.2 deletions (de novo in four
cases) did not segregate with schizophre-
nia in families.
Conclusions: Many common SNPs are
likely to contribute to schizophrenia risk,
with substantial overlap in genetic risk
factors between multiply affected families
and ses in l rge case-control st dies. Our
ﬁndings are consistentwith a role for speciﬁc
CNVs in disease pathogenesis, but the partial
segregationof someCNVswith schizophrenia
suggests that researchers should exercise
caution in using them for predictive genetic
testing until their effects in diverse popula-
tions have been fully studied.
Am J Psychiatry Levinson et al.; AiA:1–11
We report here on the ﬁrst genome-wide associ-
ation study (GWAS) in families with multiple members
with schizophrenia. Signiﬁcant associations of single-
nucleotide polymorphisms (SNPs) can suggest new
disease susceptibility mechanisms. For schizophrenia,
large GWAS analyses of common SNPs have found
associations in the major histocompatibility complex
(MHC, chromosome 6) (1–3) and several speciﬁc genes
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Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked	  for	  thousands	  of	  
volunteer	  families.	  
Pa(entsLikeMe	  

strapples	  
	  	  	  	  Male,	  21	  years	  
	  	  	  	  Chicago,	  IL	  	  
About	  strapples	  
I	  am	  diagnosed	  with	  Re`	  syndrome.	  It	  is	  a	  true	  anomaly	  for	  a	  male	  to	  be	  Re`	  and	  survive	  as	  
well	  as	  I	  have.	  I	  share	  more	  at	  my	  website.	  h`p://www.alinssite.info	  	  
See	  full	  biography	  
Interests	  
Advocacy	  	  
ALS	  Public	  Registry	  	  
Proﬁle	  Ac/vity	  45,870	  Views	  49	  Followers	  Forum	  Ac/vity	  155	  posts	  200	  helpful	  marks	  	  
Member	  since:	  Nov	  17,	  2008	  Last	  Login	  Sep	  11,	  2012	  	  
	  
Other	  Condi(ons	  
ASD	  (Au/sm	  Spectrum	  Disorder)	  First	  symptom	  Aug	  1991	  Diagnosis	  Jul	  2009	  	  
Cerebral	  Palsy	  First	  symptom	  Aug	  1991	  Diagnosis	  Dec	  2009	  	  
Epilepsy	  First	  seizure	  May	  2007	  Diagnosis	  Dec	  2009	  	  
Kyphoscoliosis	  First	  symptom	  Apr	  2005	  Diagnosis	  Sep	  2006	  	  
	  
	  
Pa(entsLikeMe	  
	  
NHS	  pa(ent	  records	  to	  revolu(onise	  medical	  
research	  in	  Britain	  
Scien/sts	  to	  hunt	  for	  lifesaving	  informa/on	  
buried	  in	  cradle-­‐to-­‐grave	  data	  collected	  by	  GPs	  
and	  hospitals	  
Ian	  Sample,	  science	  correspondent	  	  
guardian.co.uk,	  Tuesday	  28	  August	  2012	  14.06	  
EDT	  	  
	  
For	  now,	  more	  eﬀort	  should	  be	  placed	  
on	  the	  following:	  
•  Implemen/ng	  Standards	  for	  a	  “clinical-­‐grade”	  exome,	  
and	  promo/ng	  the	  “networking	  of	  science”	  model.	  
•  Focusing	  on	  rare,	  highly	  penetrant	  muta/ons	  running	  
in	  families,	  with	  cascade	  carrier	  tes/ng	  of	  even	  more	  
rela/ves	  as	  needed.	  
•  The	  genomic	  background	  is	  much	  more	  constant	  in	  
families.	  
•  The	  environmental	  background	  is	  some/mes	  more	  
constant	  in	  families.	  
•  This	  allows	  one	  to	  ﬁgure	  out	  penetrance	  of	  rare	  
variants	  in	  these	  families,	  along	  with	  other	  issues,	  
such	  as	  soma/c	  mosaicism.	  
Figure 4.	

	

Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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